NYSE:NVTA - InVitae Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.75
  • Forecasted Upside: -18.80 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$45.26
▼ -0.75 (-1.63%)
1 month | 3 months | 12 months
Get New InVitae Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.75
▼ -18.80% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for InVitae in the last 3 months. The average price target is $36.75, with a high forecast of $48.00 and a low forecast of $20.00. The average price target represents a -18.80% upside from the last price of $45.26.
Buy
The current consensus among 7 polled investment analysts is to buy stock in InVitae.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$45.00High
i
10/5/2020OppenheimerBoost Price Target$37.00 ➝ $48.00Medium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$38.00High
i
8/5/2020LADENBURG THALM/SH SHBoost Price TargetBuy$31.25 ➝ $37.25High
i
8/5/2020SVB LeerinkLower Price TargetOutperform$40.00 ➝ $34.00High
i
8/4/2020OppenheimerInitiated CoverageBuy$37.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
7/21/2020OppenheimerInitiated CoveragePositive ➝ Buy$29.00 ➝ $37.00Low
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
7/15/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $40.00Medium
i
7/1/2020BenchmarkDowngradeBuy ➝ HoldMedium
i
6/26/2020CowenBoost Price TargetOutperform$18.00 ➝ $35.00Medium
i
6/22/2020OppenheimerReiterated RatingBuy$29.00High
i
5/6/2020SVB LeerinkBoost Price TargetOutperform$20.00 ➝ $25.00High
i
4/8/2020BenchmarkLower Price TargetBuy$31.00 ➝ $20.00High
i
4/2/2020OppenheimerLower Price Target$32.00 ➝ $25.00High
i
2/20/2020CowenBoost Price TargetOutperform ➝ In-Line$20.00 ➝ $30.00High
i
8/25/2019Chardan CapitalSet Price TargetBuy$32.00High
i
Rating by Steven Wardell at Chardan Capital
8/7/2019SVB LeerinkSet Price TargetBuy$31.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
8/7/2019OppenheimerSet Price TargetBuy$34.00Medium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
8/7/2019BenchmarkReiterated RatingBuy ➝ Buy$26.00 ➝ $28.00High
i
Rating by Bruce Jackson at Benchmark Co.
7/12/2019BenchmarkBoost Price TargetBuy$22.00 ➝ $26.00Low
i
Rating by Bruce Jackson at Benchmark Co.
6/11/2019Chardan CapitalReiterated RatingBuy$30.00High
i
4/8/2019OppenheimerBoost Price TargetOutperform$21.00 ➝ $30.00Medium
i
3/4/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$29.00Low
i
2/20/2019BenchmarkBoost Price TargetBuy$17.00 ➝ $20.00High
i
Rating by Bruce Jackson at Benchmark Co.
2/20/2019JPMorgan Chase & Co.Reiterated RatingOverweight$20.00High
i
12/19/2018CIBCInitiated CoverageOutperform ➝ OutperformHigh
i
12/19/2018OppenheimerInitiated CoverageOutperform$20.00High
i
11/20/2018BenchmarkInitiated CoverageBuy ➝ Buy$17.00High
i
11/8/2018William BlairReiterated RatingMarket PerformLow
i
Rating by B. Weinstein at William Blair
11/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight$16.00High
i
2/13/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$13.00 ➝ $9.00High
i
2/13/2018BenchmarkLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00High
i
1/16/2018BenchmarkLower Price TargetBuy ➝ Buy$16.00 ➝ $11.00Medium
i
1/16/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$12.00 ➝ $10.00High
i
1/5/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$15.00High
i
11/7/2017SVB LeerinkLower Price TargetOutperform$14.00 ➝ $12.00N/A
i
8/9/2017JPMorgan Chase & Co.Reiterated RatingOverweight$14.00 ➝ $15.00Low
i
4/3/2017BenchmarkReiterated RatingBuy ➝ Buy$11.00 ➝ $16.00High
i
Rating by Raymond Myers at Benchmark Co.
2/14/2017BenchmarkUpgradeHold ➝ Buy$8.50 ➝ $11.00N/A
i
11/10/2016SVB LeerinkInitiated CoverageOutperform$12.00N/A
i
11/9/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by P. Souda at SVB Leerink LLC
11/8/2016BenchmarkReiterated RatingHold ➝ NeutralN/A
i
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$12.00 ➝ $14.00N/A
i
6/30/2016BenchmarkInitiated CoverageHold$8.50N/A
i
2/10/2016JPMorgan Chase & Co.Lower Price TargetOverweight$17.00 ➝ $12.00N/A
i
1/28/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$10.00 ➝ $8.00N/A
i
1/27/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
i
Rating by D. Leonard at SVB Leerink LLC
11/9/2015SVB LeerinkReiterated RatingOutperform$20.00 ➝ $14.00N/A
i
Rating by Dan Leonard at SVB Leerink LLC
(Data available from 10/23/2015 forward)
InVitae logo
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $45.26
$44.90
$46.31

50 Day Range

MA: $42.15
$30.23
$53.31

52 Week Range

Now: $45.26
$7.41
$55.38

Volume

1,493,689 shs

Average Volume

3,075,202 shs

Market Capitalization

$5.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03